Retigabine - positive results in Phase III study

Retigabine - positive results in Phase III study 

Results presented at the Annual Meeting of the American Epilepsy Society in
Seattle December 6 demonstrate that Retigabine as an adjunctive treatment
resulted in statistically significant reduction of seizures and that the
response dose-dependent. The study (RESTORE 2) is a randomized, double- blind,
placebo-controlled Phase III study (600mg and 900 mg) with the aim to compare
Retigabine versus placebo in patients on antiepileptic drug therapy.

Retigabine comprises a new way of affecting potassium channels in the central
nervous system.
It has been documented to treat epilepsy and has a different mechanism of action
compared to current antiepileptic therapies. According to GlaxoSmithKline and
Valeant, the registration application for the first indication, epilepsy, is
expected to be submitted early 2009 in both the U.S. and in Europe.


For more information contact:

Anders Larnholt, Investor Relations	tel. +46 709 458 878

MEDA AB (publ) is a leading international specialty pharma company. The company
specialises in marketing and pharmaceutical development in late clinical stage.
Acquisitions and long-term partnerships are fundamental factors that drive the
company's strategy. Meda is represented by its own organisations in about 40
countries. Meda's products are sold in 120 countries worldwide. The Meda share
is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit
www.meda.se.